| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6107302 | GLAXOSMITHKLINE | Guanine derivative |
Jan, 2016
(8 years ago) | |
| US5879706 | GLAXOSMITHKLINE | Valaciclovir tablets containing colloidal silicon dioxide |
Jan, 2016
(8 years ago) | |
|
US5879706 (Pediatric) | GLAXOSMITHKLINE | Valaciclovir tablets containing colloidal silicon dioxide |
Jul, 2016
(7 years ago) | |
|
US6107302 (Pediatric) | GLAXOSMITHKLINE | Guanine derivative |
Jul, 2016
(7 years ago) | |
Valtrex is owned by Glaxosmithkline.
Valtrex contains Valacyclovir Hydrochloride.
Valtrex has a total of 4 drug patents out of which 4 drug patents have expired.
Expired drug patents of Valtrex are:
- US6107302
- US5879706
- US5879706*PED
- US6107302*PED
Valtrex was authorised for market use on 23 June, 1995.
Valtrex is available in tablet;oral dosage forms.
Valtrex can be used as treatment of herpes zoster, treatment of genital herpes, treatment of cold sores, suppression of genital herpes in immunocompetent and hiv-infected individuals, reduction of risk of heterosexual transmission of genital herpes.
The generics of Valtrex are possible to be released after 19 July, 2016.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-570) | Sep 02, 2011 |
| Pediatric Exclusivity(PED) | Mar 02, 2012 |
| New Patient Population(NPP) | Sep 02, 2011 |
Drugs and Companies using VALACYCLOVIR HYDROCHLORIDE ingredient
Market Authorisation Date: 23 June, 1995
Treatment: Treatment of herpes zoster, treatment of genital herpes, treatment of cold sores, suppression of genital herpes in immunocompetent and hiv-infected individuals, reduction of risk of heterosexual trans...
Dosage: TABLET;ORAL
VALTREX family patents
